[ad_1]
Washington – The Modern pharmaceutical company He announced that he is developing against the vaccine. coronavirus A 94.5% efficiency According to a report, it meets the required performance criteria for marketing.
The company confirms this is a “better day” in the fight against the coronavirus, which it claims to have met the criteria set out in the protocol. Read its effectiveness In the next few days it will present the related documents. Final approval.
The study, known as the Cove study, recruited more than 30,000 participants. United States The report says it has been done National Institute of Allergy and Infectious Diseases (NIAID) and the United States Institute of Health, part of it Higher Institute of Health (NIH) y Biomedical company.
The results will come immediately Similar results from Pfizer And build confidence that vaccines will help eliminate the infection. Both companies used a new approach to design their vaccines.
Moderna has created a “RNA vaccine”That is, part of the coronavirus genetic code is injected into the body, allowing the immune system to make enough protein to train.
Read also: Poll: 78% of Mexicans are ready to get vaccinated against the government 19
As the Modern Report explains, the main focus of the study is based on analysis Patients with Covit-19 The second dose of the vaccine was confirmed and evaluated two weeks later.
“This first interim analysis was based on 95 cases, of which 90 cases were found in the group of people who received the Govit-19 placebo, compared to five cases found in the vaccinated group,” the announcement said.
As a second final point, the eleven severe cases developed in the placebo group, not the vaccine.
In 95 cases of Covid-19, 15 adults (over 65) and 20 participants were identified as belonging to different communities (including 12 Hispanic or Latino, 4 black or African American, 3 Asian American and 1 multi-ethnic group).
Reviewing the contraindications, Modernna states that “in general, the vaccine is well tolerated” and that “most adverse events are mild or moderate in severity” and of short duration.
Read also: World leaders demand global access to the vaccine
“Severe cases with a frequency greater than 2% or equivalent after the first dose include injection site pain (2.7%), followed by fatigue (9.7%), myalgia (8.9%), head injection site and redness after the second dose.
The company said in a statement: “This is an important moment in the development of our candidate vaccine Covit-19. We have been chasing this virus since the beginning of January, with the aim of protecting as many people as possible. People all over the world know that every day matters. “
“This positive interim analysis of our Phase 3 study has provided us with the first clinical validation that our vaccine can prevent COVID-19 disease, including acute disease,” Stephen Bonsell said in a statement.
grg
[ad_2]
Source link
